Translate
Subscribe to Blog via Email
Ronny Allan
What is the aim of this clinical trial?
The aim of this single location trial in Imperial College London is to determine whether pre-treatment with ASTX727 results in re-expression of SSTR2 in patients with metastatic NETs, using 68Ga-DOTA-TATE to image epigenetic modification of the SSTR2 locus allowing subsequent treatment with Lutathera(i.e. PRRT). Patients entered into the study will receive ASTX727 orally up to 3 to 8 days prior to receiving Lutathera treatment.
What is ASTX727?
Oral Decitabine and Cedazuridine (ASTX727) is a DNA methyltransferase (DNMT) inhibitor currently being used in a trial to facilitate oral treatment of certain drugs for adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML).
This is extremely technical, but from a study conducted by scientists at Imperial College London, they acknowledged that significant number of patients were unsuitable for (177Lu)DOTATATE due to limited SSTR2 expression. In both in vitro and in vivo treatment of NET cell lines with decitabine not only resulted in re-expression of SSTR2 but importantly, also resulted in enhanced uptake of radiolabeled SSAs, showing functionality in receptor re-expression, a concept that was independently corroborated. The clinical trial would appear to be an extension of this concept for trial in humans who will receive ASTX727 to enhance SSTR2 expression, followed by PRRT, in which (68Ga) DOTA-PET is used to assess SSTR2 re-expression. Utilizing epigenetic modifiers to allow the re-expression of a receptor of interest has the potential to improve the clinical outcome in a significant number of GEP-NET patients who would otherwise not be suitable for PRRT (citation below).
Citation: Sharma, R.; Lythgoe, M.P.; Slaich, B.; Patel, N. Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias. Cancers 2021, 13, 4181. https://doi.org/10.3390/cancers13164181
Further Reading
1. See the clinical trial document NCT05178693 “Lutathera and ASTX727 in Neuroendocrine Tumours (LANTana)”
– click here
Note: Always useful to check the inclusion and exclusion criteria in clinical trial documents. Amongst others, I think the key ones that might be on people’s minds are – prior PRRT not accepted, only for well-differentiated NETs less than Ki67 55%, tumoural uptake on [68Ga]-DOTA-TATE greater than background liver. There are many more.
2. Somatostatin Receptor Primer – click here (or on the picture)
General Clinical Trials Disclaimer
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact. If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net
The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan.
Finally
Whenever I post about a trial or study, some people get excited without understanding that these new treatments and capabilities can very often take years to come to fruition and it’s also possible that clinical trials can be halted, or that national approval agencies will not approve the final product. Plus, not everyone will be eligible, so always check the exclusion and inclusion criteria in the relevant clinical trials document. Please bear that in mind when reading studies/clinical trials posted on RonnyAllan.NET
Top 10 Posts & Pages in the last 48 hours (auto updates) (Click the titles to read them)
Thanks for reading.
I’m also active on Facebook. Like this page.
I’m also active on this Facebook page. Follow this page.
Also like this awareness page on Facebook.
Sign up for my newsletters – Click Here
My Diagnosis and Treatment History
Check out my online presentations
Check out my WEGO Health Awards
Like my new awareness page – click here or on the photo. (Like rather than follow please!)
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
Sometimes, you gotta climb that hill, even if it hurts
I started my “sometimes you gotta climb that hill” series/campaign some years so. I used it as a metaphor based on my own experience of
A spotlight on duodenal Neuroendocrine Neoplasms (dNENs)
What are Duodenal Neuroendocrine Neoplasms (dNEN)? The duodenum is technically part of the small intestine, and you can find that in most anatomy-based descriptions. One
Neuroendocrine Cancer: Awareness is key, but it must be the right message
Let me start by saying that Neuroendocrine Cancer awareness is in a better place than it was when I was diagnosed in 2010. But it
Summary of May 2023 on RonnyAllan.NET
Summary May produced the best statistics in 2023, mainly due to your support for my blog post on Maria Menounos whose announcement headlined as “Pancreatic
Getting back in the saddle
Those who follow my Facebook page Ronny Allan may remember my cycling faux pas in April causing me to bruise or fracture a rib (here
Clinical Trial: Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies (incl Neuroendocrine Neoplasms)
Who are 23andMe? I personally had not heard of 23andMe but many people in North America might have. When you first look at what they
A spotlight on Chromogranin A
What is Chromogranin A? Chromogranin A (CgA) is an acidic protein released along with catecholamines from chromaffin cells and nerve terminals. This statement alone might
Neuroendocrine Cancer: Catch them early, not late!
Diagnosing Neuroendocrine Neoplasms (NENs). It’s no secret that Neuroendocrine Neoplasms (NENs) can be difficult to diagnose, particularly well differentiated slow growing types (NETs) which can
A spotlight on Rectal Neuroendocrine Neoplasms
What are Rectal NENs Rectal Neuroendocrine Neoplasms (NENs) (rNENs) account for approximately 1-2% of all primary cancers in the rectum. The other main cancer types
